Fatal outcome surfaces in Chinese gene therapy study, raising transparency concerns

A patient with an autoimmune condition died after receiving an experimental genetic treatment developed by Shanghai-based RiboX Therapeutics, according to Endpoints News. This marks the third known fatality linked to such trials in China, which have drawn scrutiny for limited disclosure. The company had recently received regulatory approval to proceed with its studies.